LEXEO THERAPEUTICS INC (LXEO) Stock News

Lexeo Therapeutics Reports First Quarter 2025 Financial Results and Operational Highlights

Lexeo Therapeutics Reports First Quarter 2025 Financial Results and Operational Highlights...

Lexeo Therapeutics to Present New CMC Data at the 28th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

Lexeo Therapeutics to Present New CMC Data at the 28th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting ...

12 Health Care Stocks Moving In Wednesday's Intraday Session

Mentions: NEOG SLRX VNRX WORX ...

Lexeo Therapeutics Appoints Kyle Rasbach as Chief Financial Officer

Lexeo Therapeutics Appoints Kyle Rasbach as Chief Financial Officer...

12 Health Care Stocks Moving In Monday's Intraday Session

Mentions: CPHI IBIO STTK STRO ...

Lexeo Therapeutics Announces Positive Interim Phase 1/2 Data for LX2006 in Friedreich Ataxia Cardiomyopathy Supporting Advancement to Registrational Study

Lexeo Therapeutics Announces Positive Interim Phase 1/2 Data for LX2006 in Friedreich Ataxia Cardiomyopathy Supporting Advancement to Registrational Study...

Pharma Frenzy: Volatility Ignites Biotech Sector

Two biotech companies have surged on recent developments, illustrating biotech's volatility and prompting investors to evaluate potential long-term value.

Mentions: TNXP

LXEO Stock Earnings: Lexeo Therapeutics Beats EPS for Q2 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Lexeo Therapeutics (NASDAQ:LXEO) just reported results for the second quarter o...

LXEO Stock Earnings: Lexeo Therapeutics Beats EPS for Q2 2024

LXEO stock results show that Lexeo Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.

Lexeo Therapeutics Sees Biggest Retail Follower Surge Among Biotech Stocks After Record-Breaking Rally: What's The Big Draw?

The company reported an adjusted Q4 loss of $0.78 per share, beating expectations for a $0.81 loss.

Mentions: IWM VTI IBB

Lexeo Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights

Lexeo Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights...

Lexeo Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Lexeo Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference...

Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results

Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results...

Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact the Underlying Genetic Cause of APOE4-Associated Alzheimer’s Disease, at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference

Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact Underlying Genetic Cause of APOE4-Associated Alzheimer's...

Lexeo Therapeutics to Present New Interim Data from Phase 1/2 Trial of LX1001 at the Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Conference

Lexeo Therapeutics to Present New Interim Data from Phase 1/2 Trial of LX1001 at the Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Conference...

Lexeo Therapeutics to Participate in Upcoming Investor Conferences

Lexeo Therapeutics to Participate in Upcoming Investor Conferences - September 2024...

Lexeo Therapeutics Reports Second Quarter 2024 Financial Results and Operational Highlights

Announced positive interim data from Phase 1/2 studies in Friedreich ataxia (FA) cardiomyopathy, which showed LX2006 was well tolerated with no...

Why Top 4% Biotech Stock Lexeo Therapeutics Just Gave Up A Breakout

The company is in the early stages of testing a gene therapy for the heart complications of a genetic disease.

Lexeo Therapeutics Announces Positive Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy

Achieved mean reduction in left ventricular mass index (LVMI) of 11.4% at 12 months and 18.3% at 18 months in participants with elevated LVMI at baseline ...

Lexeo Therapeutics Announces Investor Webcast to Report Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy on Monday, July 15, 2024

NEW YORK, July 11, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering...

Lexeo Therapeutics Appoints Tim Van Hauwermeiren to its Board of Directors

Lexeo Therapeutics Appoints Tim Van Hauwermeiren to its Board of Directors ...